BioSpace News Archive

According to Nova one advisor, the global insilico clinical trials market size was valued at USD 2.6 billion in 2021, and is predicted to be worth around USD 5.0 billion by 2030, registering a CAGR of 7.3% during the forecast period 2022 to 2030.

According to Nova one advisor, the global Life Science Analytics market gathered revenue around USD 7.1 Billion in 2020 and market is set to grow USD 15.2 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 8.2% during the prediction period 2021 to 2027.

According to Nova one advisor, the global Urgent Care Apps market gathered revenue around USD 2.1 Billion in 2020 and market is set to grow USD 8.9 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 40.1% during the prediction period 2021 to 2027.

Omeza today announced that the Centers for Medicare and Medicaid Services (CMS) has confirmed a HCPCS reimbursement code for Omeza® Collagen Matrix; code A2014, “Omeza collagen matrix, per 100 mg” was established to describe the product.

MY01, Inc. today announced that interim data used in the diagnosing of Acute Compartment Syndrome (ACS) from two ongoing, prospective, multi-center studies will be presented at the Orthopaedic Trauma Association (OTA) Annual Meeting in Tampa, Florida.

OvaryIt, LLC announces their Notice of Award for a Phase 1 Small Business Innovation Research grant from the National Institutes of Health.

SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to accelerate a cure for facioscapulohumeral muscular dystrophy, announced an investment of US$10M million in Vita Therapeutics; a cell engineering company harnessing the power of genetics to develop novel cellular therapies to treat muscular dystrophies and solid tumours.

One the many unhealthy outcomes of America’s state of obesity occurs when people start building up excess fat around their liver, a condition called non-alcoholic fatty liver disease.

ERYTECH Pharma from The Nasdaq Stock Market LLC dated October 7, 2022, indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy to be extended by three months.